The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants

Joseph M. Mrus, Michael S. Yi, Mark H. Eckman, Joel Tsevat

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective. To quantify the costs and effectiveness of different strategies for ruling out HIV infection in infants born to HIV-infected mothers in the United States. Methods. The authors assessed 4 different testing strategies that incorporated serial HIV DNA polymerase chain reaction (PCR) testing with or without enzyme-linked immunosorbent assay (ELISA) antibody testing. Testing costs, false reassurance rates, and incremental cost-effectiveness ratios were compared for the 4 strategies. Results. In HIV-exposed infants, HIV DNA PCR testing at birth, 1 month, and 4 months of age results in a false reassurance rate of 21 per million (at a 2% transmission rate). Adding an ELISA test lowers the false reassurance rate to 0.052 per million at a cost of $570,000 per additional case detected; adding another PCR lowers the false reassurance rate to 1.49 per million at a cost of $720,000 per additional case detected compared with the 3-PCR strategy. At a high transmission rate (20%), there would be substantially more erroneously negative results (false reassurance rate is 256 per million with PCR testing at birth, 1 month, and 4 months) and consequently more favorable cost-effectiveness ratios with additional testing: $47,000 per additional case detected by adding 1 ELISA test and $59,000 per additional case detected by adding another PCR test. Conclusions. False-negative HIV results after serial testing in exposed infants are rare, and the incremental cost-effectiveness ratios of additional tests are substantial at low transmission rates. However, the false reassurance rate increases considerably with a 3-PCR strategy and additional testing becomes more cost-effective at greater transmission rates; therefore, additional testing may be warranted in infants at greater risk of infection.

Original languageEnglish (US)
JournalMedical Decision Making
Volume22
Issue number5 SUPPL.
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

HIV Infections
Cost-Benefit Analysis
HIV
Polymerase Chain Reaction
Costs and Cost Analysis
Enzyme-Linked Immunosorbent Assay
DNA-Directed DNA Polymerase
Parturition
Mothers
Antibodies
Infection

Keywords

  • HIV
  • Infants
  • Testing
  • Vertical transmission

ASJC Scopus subject areas

  • Health Informatics
  • Public Health, Environmental and Occupational Health
  • Nursing(all)
  • Health Information Management

Cite this

The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants. / Mrus, Joseph M.; Yi, Michael S.; Eckman, Mark H.; Tsevat, Joel.

In: Medical Decision Making, Vol. 22, No. 5 SUPPL., 01.09.2002.

Research output: Contribution to journalArticle

@article{d57dffbc9f1a495fbe133093bea6c733,
title = "The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants",
abstract = "Objective. To quantify the costs and effectiveness of different strategies for ruling out HIV infection in infants born to HIV-infected mothers in the United States. Methods. The authors assessed 4 different testing strategies that incorporated serial HIV DNA polymerase chain reaction (PCR) testing with or without enzyme-linked immunosorbent assay (ELISA) antibody testing. Testing costs, false reassurance rates, and incremental cost-effectiveness ratios were compared for the 4 strategies. Results. In HIV-exposed infants, HIV DNA PCR testing at birth, 1 month, and 4 months of age results in a false reassurance rate of 21 per million (at a 2{\%} transmission rate). Adding an ELISA test lowers the false reassurance rate to 0.052 per million at a cost of $570,000 per additional case detected; adding another PCR lowers the false reassurance rate to 1.49 per million at a cost of $720,000 per additional case detected compared with the 3-PCR strategy. At a high transmission rate (20{\%}), there would be substantially more erroneously negative results (false reassurance rate is 256 per million with PCR testing at birth, 1 month, and 4 months) and consequently more favorable cost-effectiveness ratios with additional testing: $47,000 per additional case detected by adding 1 ELISA test and $59,000 per additional case detected by adding another PCR test. Conclusions. False-negative HIV results after serial testing in exposed infants are rare, and the incremental cost-effectiveness ratios of additional tests are substantial at low transmission rates. However, the false reassurance rate increases considerably with a 3-PCR strategy and additional testing becomes more cost-effective at greater transmission rates; therefore, additional testing may be warranted in infants at greater risk of infection.",
keywords = "HIV, Infants, Testing, Vertical transmission",
author = "Mrus, {Joseph M.} and Yi, {Michael S.} and Eckman, {Mark H.} and Joel Tsevat",
year = "2002",
month = "9",
day = "1",
language = "English (US)",
volume = "22",
journal = "Medical Decision Making",
issn = "0272-989X",
publisher = "SAGE Publications Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants

AU - Mrus, Joseph M.

AU - Yi, Michael S.

AU - Eckman, Mark H.

AU - Tsevat, Joel

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Objective. To quantify the costs and effectiveness of different strategies for ruling out HIV infection in infants born to HIV-infected mothers in the United States. Methods. The authors assessed 4 different testing strategies that incorporated serial HIV DNA polymerase chain reaction (PCR) testing with or without enzyme-linked immunosorbent assay (ELISA) antibody testing. Testing costs, false reassurance rates, and incremental cost-effectiveness ratios were compared for the 4 strategies. Results. In HIV-exposed infants, HIV DNA PCR testing at birth, 1 month, and 4 months of age results in a false reassurance rate of 21 per million (at a 2% transmission rate). Adding an ELISA test lowers the false reassurance rate to 0.052 per million at a cost of $570,000 per additional case detected; adding another PCR lowers the false reassurance rate to 1.49 per million at a cost of $720,000 per additional case detected compared with the 3-PCR strategy. At a high transmission rate (20%), there would be substantially more erroneously negative results (false reassurance rate is 256 per million with PCR testing at birth, 1 month, and 4 months) and consequently more favorable cost-effectiveness ratios with additional testing: $47,000 per additional case detected by adding 1 ELISA test and $59,000 per additional case detected by adding another PCR test. Conclusions. False-negative HIV results after serial testing in exposed infants are rare, and the incremental cost-effectiveness ratios of additional tests are substantial at low transmission rates. However, the false reassurance rate increases considerably with a 3-PCR strategy and additional testing becomes more cost-effective at greater transmission rates; therefore, additional testing may be warranted in infants at greater risk of infection.

AB - Objective. To quantify the costs and effectiveness of different strategies for ruling out HIV infection in infants born to HIV-infected mothers in the United States. Methods. The authors assessed 4 different testing strategies that incorporated serial HIV DNA polymerase chain reaction (PCR) testing with or without enzyme-linked immunosorbent assay (ELISA) antibody testing. Testing costs, false reassurance rates, and incremental cost-effectiveness ratios were compared for the 4 strategies. Results. In HIV-exposed infants, HIV DNA PCR testing at birth, 1 month, and 4 months of age results in a false reassurance rate of 21 per million (at a 2% transmission rate). Adding an ELISA test lowers the false reassurance rate to 0.052 per million at a cost of $570,000 per additional case detected; adding another PCR lowers the false reassurance rate to 1.49 per million at a cost of $720,000 per additional case detected compared with the 3-PCR strategy. At a high transmission rate (20%), there would be substantially more erroneously negative results (false reassurance rate is 256 per million with PCR testing at birth, 1 month, and 4 months) and consequently more favorable cost-effectiveness ratios with additional testing: $47,000 per additional case detected by adding 1 ELISA test and $59,000 per additional case detected by adding another PCR test. Conclusions. False-negative HIV results after serial testing in exposed infants are rare, and the incremental cost-effectiveness ratios of additional tests are substantial at low transmission rates. However, the false reassurance rate increases considerably with a 3-PCR strategy and additional testing becomes more cost-effective at greater transmission rates; therefore, additional testing may be warranted in infants at greater risk of infection.

KW - HIV

KW - Infants

KW - Testing

KW - Vertical transmission

UR - http://www.scopus.com/inward/record.url?scp=0036739975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036739975&partnerID=8YFLogxK

M3 - Article

C2 - 12369230

AN - SCOPUS:0036739975

VL - 22

JO - Medical Decision Making

JF - Medical Decision Making

SN - 0272-989X

IS - 5 SUPPL.

ER -